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Abstract
Background Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational 
genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed 
to establish if normal FFPE breast tissue could be used as an alternative to blood.
Methods Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in 
the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-
dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents 
(Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 
(Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy num-
ber abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate 
somatic variants and CNA, respectively.
Results Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was 
good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% 
were more difficult to validate irrespective of the type of germline DNA used. Pearson’s correlation coefficients for paired 
comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94.
Conclusions There is good correlation between the somatic mutations and CNA called using archived blood or normal breast 
tissue as germline reference material.
Keywords Germline determinants · Whole exome sequencing · Breast cancer · Archival formalin fixed paraffin embedded 
tissue
Introduction
Bio-banked formalin-fixed and paraffin-embedded (FFPE) 
tissues provide an excellent opportunity for translational 
research. Reductions in cost and the wider availability of 
next-generation sequencing (NGS) in the research commu-
nity has meant that this sequence-level analysis is increas-
ingly being used in cancer genetics. For DNA studies, 
matched germline blood is typically used for exome and 
whole genome sequencing to provide a “normal” refer-
ence against which an individual patient’s abnormal tumour 
DNA can be compared. Historical clinical sample collection, 
prior to the widespread availability of NGS, did not usually 
include collection of germline blood. An important prag-
matic question, therefore, arises as to whether surrounding 
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normal tissue can be used as an alternative reference ger-
mline from these archival samples. This proof-of-principle 
study was designed to assess the feasibility and validity of 
using normal breast tissue as a reference germline in a small 
cohort of patients where all three of normal breast tissue, 
breast tumours and blood samples were available in a his-
torical cohort.
“Field cancerisation” describes areas around tumours 
consisting of histologically normal, yet genetically aberrant 
cells, and is well-recognised in breast cancer [1]. Genomic 
alterations including allelic imbalance and loss of heterozy-
gosity (LOH) [2], aneusomy [3] and dysfunctional telomeres 
[4] have been demonstrated in histopathologically normal 
breast lobules, and the frequency of some aberrations has 
shown a correlation with distance from the tumour [5]. Such 
changes typically occur in only a proportion of epithelial 
cells and are unlikely to be present in other cell types pre-
sent in normal breast tissue. Other cell types include adi-
pocytes, stromal, endothelial and smooth muscle cells, and 
possibly cells associated with inflammation or the immune 
response. The impact of field cancerisation may therefore 
be minimised by selection of normal breast tissue located at 
a distance from the tumour, which will typically include a 
mixture of epithelial and non-epithelial cells.
A previous study used polymerase chain reaction (PCR) 
to assess five genotypes with frequent LOH in breast cancer 
and demonstrated 100% concordance for genotyping from 
FFPE normal tissue adjacent to tumour and from blood 
[6]. The International cancer genome consortium (ICGC) 
conducted a large sequencing study to assess the landscape 
of somatic mutations in 560 breast cancer whole-genome 
sequences [7]. For 96 patients adjacent breast tissue was 
used as the source of normal DNA, whereas for 353 patients 
blood was used as the source of germline DNA. Although a 
formal comparison between the sources of germline DNA 
was not reported, no significant differences in sequencing 
findings were noted in cases using adjacent breast versus 
those using blood for germline DNA.
The cancer genome atlas (TCGA) recently conducted a 
multi-platform analysis using fresh frozen samples. DNA 
defects, epigenetic changes and gene expression profiles 
were reported from cancer-adjacent breast tissue, defined as 
at least 2 cm from breast tumour [8]. Although changes con-
sistent with field cancerisation were identified, these did not 
appear to prohibit use of normal breast tissue as the germline 
reference. Sequence data from tumours and cancer-adjacent 
breast tissue were each compared with blood, and therefore 
the genomic comparisons conducted in the TCGA analysis 
were not the same as our study.
The work in this study aimed to establish if DNA 
extracted from archived normal breast tissue blocks can be 
used as a surrogate germline reference by comparing exome 
sequencing of breast tumours using either matched blood 
DNA or normal breast DNA as the germline reference.
Methods
Selection of patient samples
Five patients with contemporaneous plasma and breast sam-
ples were selected from different centres participating in the 
START radiotherapy fractionation trial (ISRCTN59368779), 
so as to represent a cross section of the larger trial cohort. 
Matched archival FFPE blocks for tumour tissue and normal 
breast tissue plus frozen blood samples for these patients 
were identified. The samples had been stored for at least 
14 years. Normal breast tissue blocks were chosen that were 
considered as free as possible of tumour cell contamination 
or pre-malignant change, following review of Haematoxylin 
and Eosin (H & E) sections by a specialist breast cancer 
pathologist. This means that individual sections flanking the 
H & E section were highly likely to be free of malignant 
or pre-malignant change. Eligibility criteria for the START 
trial included complete macroscopic excision of tumour by 
breast-conserving surgery or mastectomy (ideally, no micro-
scopic evidence of invasive or in situ cancer at, or within 
1 mm of, a resection margin). Three patients had undergone 
lumpectomy plus wide local excision and two patients had 
undergone mastectomy. It was not possible to retrospectively 
quantify the exact distance from tumour but the existence 
of tumour-free blocks suggests the margins from invasive 
tumour were generous.
DNA extraction
Sections (3 × 8 µm) were cut from tissue blocks, and stained 
with Nuclear Fast Red to guide macro-dissection. Tumour 
areas were macro-dissected following demarcation of malig-
nant tissue on an H & E slide by a specialist breast patholo-
gist, with the aim of maximising tumour purity. Normal 
breast tissue blocks did not undergo any macro or micro-
dissection. Tumour and normal breast DNA was extracted 
using the QIamp DNA FFPE Tissue Kit (Qiagen) as per 
the protocol instructions. DNA was eluted in approximately 
70 µl of ATE buffer and stored at − 20 °C. DNA from blood 
was extracted using the Qiagen Blood and Tissue kit fol-
lowing the manufacturer’s instructions. DNA was quantified 
using Qubit fluorometry.
Exome sequencing and data analysis
Targeted exome capture was performed using SureSelect 
Human All Exome v5 reagents (Agilent). Illumina paired-
end libraries were prepared from the captured target regions 
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and sequenced on a HiSeq2500 (Illumina) using v4 chemis-
try acquiring 2 × 75 bp reads.
BWA-mem (v0.7.5a) was used to align reads to the human 
reference genome (GRCh37). PCR duplicates were removed 
prior to further processing and variant detection. Somatic 
variant calling on tumour samples paired with matched nor-
mal samples was performed to identify both single nucleo-
tide variants (SNVs) and small insertions/deletions (indels) 
of < 30 bp. Somatic SNVs were identified using MuTect 
(v1.1.4; http://www.broad insti tute.org/cance r/cga/mutec t). 
Somatic indels were selected using the Genome Analysis 
Toolkit (GATK) v3.3.0. All somatic variants were annotated 
using the SnpEff [9], which provided information on genes 
affected by mutations and the likely consequences for the 
encoded gene products. Variants called in regions not cov-
ered by the capture probes were excluded, as were those with 
genotype quality scores below 20, alternative read count less 
than 10, variant allele frequencies (VAFs) less than 2% and 
coverage less than 20 reads in either sample.
CNVKit v0.8.5 [10] was used to derive somatic copy 
number alterations (CNA) by comparing the tumour sam-
ple to the matched germline sample (normal breast tissue 
or blood). CNVkit calculates the mean read depths for on-
target and off-target reads which are then combined for each 
interval. The combined mean read depths were normalised 
against the control sample and corrected for systematic 
biases (such as GC content) to obtain the log2 copy number 
ratios. Discrete copy number segments were generated from 
the bin level log2 ratio values using the circular binary seg-
mentation (CBS) algorithm [11], which is available as one of 
the segmentation methods within CNVKit. The copy num-
ber values and frequency of heterozygous mutations were 
used for the estimation of tumour purity using the ASCAT 
software package (8). The observed log2 copy number 
ratios were adjusted using the purity estimates to generate 
the absolute copy number values. Adjacent segments with 
the same allele specific copy number were merged using the 
“filter cn” option in CNVkit.
Two different approaches for description of CNA were 
used; matched and pooled. First, individually matched 
tumour versus normal tissue or blood comparisons was 
conducted. Second, a pooled analysis using all tumour-free 
normal breast tissue samples or all blood samples as refer-
ence germline, compared to each individual tumour sample, 
was performed [12].
Validation of somatic variants using a customised 
AmpliSeq panel
A customised Ampliseq panel assessing 139 somatic vari-
ants detected using blood or normal breast tissue as refer-
ence was developed using the Ion AmpliSeq Designer. This 
panel was designed to validate mutations with a discrepant 
call between normal breast and blood, and variants of par-
ticular relevance to cancer [cancer genomics consortium 
(CGC) genes]. In order to explore the limit of detection of 
variants, it also included a number of variants with a VAF 
on exome sequencing that was lower than 10%. As there 
were slightly more somatic variants detected using blood 
as germline versus normal breast, the Ampliseq panel was 
enriched for discrepant variants detected using blood as the 
germline (n = 35) rather than normal breast as the germline 
(n = 4).
Sequencing libraries were prepared using the automated 
Ion Chef library preparation protocol, using a single pool 
of 10 ng of DNA. Libraries were templated using the Ion 
Chef (Life Technologies), and sequenced on a PI chip using 
the Ion PI HiQ sequencing reagents (Life Technologies), 
520 flows, with an average amplicon length of 117 bp, to 
a minimum depth of ×18,000. The sequencing resulted in 
3,363,175–7,408,316 reads per sample. The sequencing data 
were processed using the Ion torrent suite v5.0.4. Reads 
were aligned to the human reference genome (GRCh37). 
Coverage data were generated using the Coverage Analysis 
plugin v5.2. Ion torrent Variant caller (TVC) plugin v5.2 
with no Hotspot region and the configuration “Somatic 
Low Stringency” was used for calling variants. The vari-
ants called in the Ampliseq panel were then compared with 
the Illumina exome sequencing data.
Validation of copy number abnormalities using 
digital polymerase chain reaction (ddPCR)
Droplet digital PCR (ddPCR) was used to validate copy 
number abnormalities. ddPCR was performed on a QX200 
digital PCR system (Bio-Rad) using the assays described 
in table S1. CGC genes with the highest copy number gain 
(≥ 4 absolute copies) were prioritised as these are likely 
to be of most clinical impact and ddPCR has been shown 
to detect these robustly [13, 14]. Genes showing different 
copy number gain using either blood or normal breast as 
a reference were also prioritised to indicate which refer-
ence germline provided most accurate estimation of the 
relevant CNA. 1–2 ng of tumour tissue DNA was used per 
assay. Reactions were prepared using digital PCR Super-
mix for probes (Bio-Rad) and a QX200 droplet generator, 
this system produces approximately 20,000 droplets per 
reaction. PCR experiments were run on a 96-well plate 
on a G-storm GS4 thermal cycler, incubating the plates at 
95° for 10 min followed by 40 cycles of 95° for 15 s and 
60° for 60 s, then 10 min incubation at 98°. Plates were 
read on a Bio-Rad QX200 droplet reader with QuantaSoft 
v1.6.6.0320 software to quantify the number of droplets 
positive for the genes being assessed. Four reference genes 
were used for each test gene, together with at least two 
negative control wells with no DNA in every run. Positive 
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and negative controls using cell lines with and without the 
relevant copy number alteration, respectively, were also 
included in each experiment. CNA for target genes were 
calculated as a ratio with the median of the four multi-
plexed reference genes.
Results
Quality of NGS
Sample description, library size, exome capture and sequenc-
ing metrics are displayed in Table 1. Overall, these indicate 
that the DNA libraries were of good quality and exome cap-
ture was performed robustly with more than 100X median 
coverage for all samples. Exome capture and coverage was 
slightly lower for blood samples (median depth 107X–125X) 
than FFPE samples (median depth 134X–167X).
Somatic variant detection
Following variant filtration, the number of somatic vari-
ants (either SNVs or small indel) called per tumour using 
blood as a germline reference ranged from 11 to 341 and 
the number of variants called using normal breast tissue as 
a germline reference ranged from 12 to 321. The overlap of 
somatic variants called on tumour versus blood and tumour 
versus normal breast tissue is shown in Fig. 1 and ranged 
from 76.9 to 93.6% (Table 2, S2). This indicates a good 
agreement between variants called using either germline 
reference. The specific somatic variants identified for each 
sample, and using both germline samples, are tabulated in 
the supplemental data. Somatic variants that are known 
recurrent driver mutations in breast cancer [7, 15, 16] are 
also tabulated, for which agreement in calling using either 
germline remains very good (table S3, S4, S5).
Somatic variants identified using exome sequencing 
were validated using targeted sequencing consisting of an 
Ampliseq panel to test 139 selected variants (the specific 
variants tested are listed in the supplemental appendix, 
table S6). As outlined in the “Methods” section, variants 
with discrepant calls between each germline and variants 
of specific relevance to cancer were prioritised in this 
panel. 110/139 (79.1%) of mutations were called using the 
Table 1  Sequencing quality control
FFPE formalin-fixed paraffin-embedded
Sequencing parameter FFPE samples (n = 10) Blood (n = 5)
Library size (bp) 236–278 324–328
Exome capture % mapped 89–94% 96%
% Duplicates 10–15% 6%
% On targets 74–78% 70–74%
Median depth 134X–167X 107X–125X
Fig. 1  The overlap of somatic variants called with blood or normal breast tissue as germline reference
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Ampliseq panel. Of the 29 mutations that were not success-
fully called using the Ampliseq panel, but present in the 
exome sequencing data, 19 occurred at VAF less than 10% 
in exome sequencing and 11 of these had VAF less than 5%. 
A further three mutations in the Ampliseq panel had lower 
than average coverage (< 1000 reads), and two mutations 
had poor mapping quality. This indicates a number of the 
mutations that were not successfully called had identifiable 
poor quality metrics.
Thirty nine of the 41 total somatic variants with a dis-
crepant call between normal breast and blood were included 
in the Ampliseq panel. Of these, 35 variants were detected 
using blood and not normal breast, and four variants were 
detected using normal breast and not blood. Of the 39 dis-
crepant variants in the Ampliseq panel, successful calls were 
obtained for 19 variants, all of which had been identified 
using blood as the germline, and not normal breast tissue. 
For the remaining 21 variants, there was no coverage in the 
relevant regions and hence it was not possible to discern 
mutation status. Manual review of the 19 variants sug-
gested that for the majority of variants, the relevant base 
change only occurred in a small number of sequencing reads 
and often towards the end of reads (where read qualities 
decrease). In addition, the majority of changes were G to A 
and C to T base changes. Although it is not possible to defin-
itively categorise these changes, the manual review indicates 
that both sequencing error and FFPE artefact explain a sub-
stantial proportion of these discrepancies.
Over 300 somatic variants were called with each refer-
ence germline from sample number 2. This sample may have 
been a hypermutated tumour arising for example from mis-
match repair deficiency or APOBEC-induced mutagenesis 
(see supplemental data for COSMIC somatic mutation sig-
natures, figure S1). The high total number of somatic vari-
ants called in sample 2 means that it is not surprising that 15 
of the 19 (78.9%) variants with discrepant calls arose from 
this sample. It is possible that field cancerisation explains 
some of the discrepant calls in this sample; however, FFPE-
induced artefact may have also increased the likelihood of 
discrepant calls.
Matched analysis of CNA
Estimates of tumour purity by a specialist histopathologist 
and the ASCAT analysis software package ranged from 52 
to 90% (table S7). CNA detected using either matched blood 
or normal breast tissue as germline material are shown as 
copy number profiles and scatter plots in Fig. 2 for patients 
1, 4 and 5, respectively, and for patients 2 and 3 in the sup-
plementary appendix (figure S2). Visual comparison of these 
plots suggests considerable variation in genomic instabil-
ity between samples but overall a good correlation between 
CNA identified using either germline reference. Pearson’s 
correlation coefficient for paired comparisons of CNA using 
either reference ranged from 0.70 to 0.94.
Validation of CNA was carried out using ddPCR for five 
genes. As explained above, these genes were selected as 
Table 2  The overlap of somatic variants (both SNVs and short indels) called in tumour using either blood or normal breast tissue as the germline 
reference using exome sequencing and targeted Ampliseq validation
SNV single nucleotide variation
Exome sequencing
Sample no. Total variants versus 
normal breast tissue
Total variants versus blood Shared variants Percentage of variants shared using 
normal breast or blood as reference (%)
1 29 30 27 84.38
2 321 341 320 93.57
3 12 11 10 76.92
4 85 90 84 92.31
5 55 59 55 93.22
Targeted Ampliseq validation
Sample no. No of variants with 
results
Variant present in exome 
sequencing using blood as 
reference
Variant present in exome sequenc-
ing using normal breast as refer-
ence
Percentage of shared exome sequencing 
variants validated by Ampliseq panel 
(%)
1 15 15 14 93.3
2 57 57 41 71.9
3 2 2 2 100.0
4 28 28 27 96.4
5 8 8 7 87.5
Total 110 110 91
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having gains of at least four copies using at least one ger-
mline reference from the exome sequencing output. Five out 
of six gains (83.3%) were validated using ddPCR as shown 
in Table 3.
Pooled analysis of CNA
Following matched analysis of CNA, all five blood samples 
were combined to give a ‘pooled blood germline reference’ 
and all five normal breast samples were combined to give a 
‘pooled normal breast reference.’ We considered this might 
be a useful approach to reduce sequencing noise, such as 
FFPE-induced artefact, from individual sample compari-
sons. These pooled references were then compared with 
individual tumour samples. Overall, these comparisons 
did not improve resolution of CNA and instead appeared 
to add artefactual noise. Copy number profiles using these 
pooled comparisons for patients 1 and 5 are shown in the 
supplementary appendix figure S3. A limitation of these 
Fig. 2  Copy number profiles using normal breast or blood as ger-
mline reference and correlation between references. a and b Copy 
number profiles showing CNA called using both normal breast and 
blood as germline, respectively, for patient 1, c Scatterplot showing 
correlation of CNA using normal breast or blood as germline patient 
1. d and e Copy number profiles showing CNA called using both nor-
mal breast and blood as germline respectively for patient 4, f Scat-
terplot showing correlation of CNA using normal breast or blood 
as germline patient 4. g and h Copy number profiles showing CNA 
called using both normal breast and blood as germline respectively 
for patient 5, i Scatterplot showing correlation of CNA using normal 
breast or blood as germline patient 5. CNA copy number alteration, 
BL blood, NB normal breast tissue
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pooled comparisons is that they were derived from only 
five patients.
Discussion
This study sought to identify if matched normal breast tis-
sue from FFPE blocks, free of malignant or pre-malignant 
change on immunohistochemistry, could provide a reliable 
source of germline DNA with which tumour DNA could be 
compared using whole exome NGS. To help establish relia-
bility, matched blood and tumour DNA were also compared. 
Findings from NGS were validated with targeted sequenc-
ing using an Ampliseq panel and droplet digital PCR. We 
acknowledge the small sample size which limits a rigorous 
assessment of the impact of factors such as specimen age 
on outcomes. However, this was a proof-of-principle study 
based on patients where all three of blood, normal tissue 
and tumour samples were available from a historical cohort.
We were able to prepare libraries and carry out whole 
exome sequencing using DNA from old archival FFPE sam-
ples retrieved from different treatment centres. This was 
despite the effects that fixation can have on DNA including 
hydrolysis, deamination and DNA–protein cross-linking, all 
of which can compromise library production. In addition, a 
good correlation between genomic aberrations called with 
blood as reference versus those called with normal tissue 
from the tumour resection specimen was seen.
With the use of stringent filtration criteria, there was a 
very good agreement between somatic variants identified, 
including for known recurrent driver mutations in breast 
cancer [7, 15, 16], using either normal breast tissue or blood 
as a germline reference. Our filtration criteria were selected 
based on the MSK-IMPACT experience [12]. Whilst it is 
possible that less stringent criteria may have identified more 
true somatic variants (see supplementary data, table S3, 
S8), our concern is that more false positive variants, typi-
cally induced by FFPE artefact, would also have resulted. 
Overall, as expected, variants with a VAF of more than 10% 
were validated most consistently. Almost all variants with 
a discrepant call between each germline sample on exome 
sequence were included in the validation panel. Those dis-
crepant calls that were successfully sequenced using the 
Ampliseq panel were validated as true somatic variants. It 
is difficult to confirm whether such discrepant calls using the 
different germline references relate to FFPE-induced arte-
fact, sequencing error or field cancerisation, however, it is 
relevant that these discrepancies occurred infrequently and 
represented less than 10% of all variant calls.
It is encouraging that correlation in CNA using either 
reference germline was also very good across the five ana-
lysed samples. If possible, fresh frozen tissue is increasingly 
used for NGS, particularly whole genome or whole exome 
sequencing, because it avoids the artefacts associated with 
formalin fixation. Our results suggest it is reasonable to use 
FFPE tissue in this context. We recognise that a limitation 
of this study is that the ddPCR platform used for validation 
only enabled reliable assessment of copy number gains with 
four or more copies, and not losses, and that a fairly small 
number of genes were selected for validation.
We attempted a number of strategies to try and reduce 
noise from copy number data, including the use of pooled 
references and trying different segmentation and filtering 
approaches. Using the CBS segmentation method, along 
with the CNVkit “filter” option, removed a significant pro-
portion of the spurious copy number segments; however, we 
did not see any significant improvement using the pooled 
reference approach. This could be due to the fact that our 
pooled comparison only used five samples. Most clinical 
studies with a pooled reference would involve a much larger 
pool of reference samples which is likely to improve reli-
ability of CNA detection [12]. The use of online repositories 
of pooled reference germline DNA, e.g. from The Cancer 
Genome Atlas (TCGA) or International Cancer Genome 
Consortium (ICGC) databases could be an alternative source 
of germline genomic data.
The recently reported analysis by TCGA of DNA defects, 
epigenetics and gene expression in cancer-adjacent breast 
Table 3  ddPCR validation of 
CNA
ddPCR droplet digital polymerase chain reaction
Gene Sample no. Exome sequencing (absolute copy 
number)
ddPCR ratio ddPCR result
Tumour versus 
normal breast
Tumour versus 
blood
MALAT1 2 3 5 2.07 Gain
4 3 4 1.69 Gain
IKBKB 1 3 5 1.84 Gain
TERT 4 4 3 2.13 Gain
HIST1H3B 2 3 5 0.92 No gain
IRF4 1 4 3 1.54 Gain
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tissue [8] concluded that approximately 40% of benign-
appearing breast-adjacent tissue harboured genomic defects 
in DNA copy number, sequence, methylation status or in 
RNA sequence. However, for the 40 samples that under-
went exome sequencing, clear detectable CNA were rare, 
occurring in 10% or less of cases. In addition, although 25% 
of cancer-adjacent samples had moderate to high levels of 
tumour-like somatic mutations, the variant allele fraction 
(VAF) was typically low. For example, five out of six muta-
tions seen in TP53 occurred at a VAF of less than 1%, all 
of these mutations would have been filtered by the stringent 
criteria typically used for FFPE samples and in this study. 
Whilst the field cancerisation changes characterised in detail 
in the TCGA report are important, we do not believe that 
they invalidate the use of FFPE normal breast DNA as a ger-
mline reference. It is important that careful histopathological 
review of normal breast tissue is carried out and appropri-
ate filtering of somatic variants. We propose exclusion of 
somatic variants with genotype quality scores below 20, 
alternative read count less than 10, variant allele frequencies 
(VAFs) less than 2% or coverage less than 20 reads.
In summary, this study sought to establish if archival 
DNA extracted from histologically normal FFPE breast tis-
sue blocks could be used as a germline reference against 
tumour DNA, when germline blood is not available. It is 
relevant that we used old archival tissue samples retrieved 
from different treatment centres where they had been stored 
for at least 14  years. Somatic variants identified using 
either matched blood or normal breast tissue had a very 
good agreement, suggesting that normal breast tissue can 
be used as a reliable surrogate to identify these aberrations 
with appropriate filtration criteria. Such filtration criteria 
appear to minimise the impact of both FFPE-induced arte-
fact and any field cancerisation changes that may be present. 
Although CNA were more complicated to directly compare, 
copy number abnormality calls were consistent using either 
germline reference and key copy number gains were vali-
dated. Overall, this study suggests that normal breast DNA 
from archival FFPE blocks lacking malignant or pre-malig-
nant change can be used as a surrogate germline and offers 
a robust alternative to use of DNA from blood for whole 
exome sequencing.
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